Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 2,601 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $11.72, for a total transaction of $30,483.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of NASDAQ MNTA opened at $11.78 on Friday. Momenta Pharmaceuticals, Inc. has a 1-year low of $9.51 and a 1-year high of $29.30. The business has a fifty day moving average of $11.32.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Friday, August 2nd. The biotechnology company reported ($1.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.74). The company had revenue of $5.18 million during the quarter, compared to analyst estimates of $9.20 million. Momenta Pharmaceuticals had a negative return on equity of 55.24% and a negative net margin of 324.41%. Momenta Pharmaceuticals’s revenue for the quarter was down 60.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.91) earnings per share. Analysts predict that Momenta Pharmaceuticals, Inc. will post -2.5 earnings per share for the current year.
Several equities analysts have recently issued reports on the stock. ValuEngine raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday. BidaskClub raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Cantor Fitzgerald set a $16.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, May 2nd. Finally, Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $22.23.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
See Also: Why do corrections happen?
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.